TME Pharma is a clinical-stage company dedicated to developing innovative therapies for the treatment of aggressive cancers. With a focus on the tumor microenvironment (TME), our approach disrupts the tumor's protection mechanisms against the immune system and impedes tumor repair by neutralizing chemokines within the TME. By working in conjunction with other treatments, our strategy weakens tumor defenses and enhances therapeutic impact.

Our ongoing clinical programs in glioblastoma and pancreatic cancer have yielded promising results, and we have plans for further development. In fact, our recent data update on the GLORIA trial in glioblastoma showcased a complete or near-complete response in 50% of patients in the expansion arm. As a company committed to scientific advancement, we actively collaborate with experts and seek cutting-edge technologies to tackle the challenges of the TME.

Our dedication to innovation is demonstrated through our pipeline of therapies and our scientific publications. At TME Pharma, we are driven to make a meaningful impact in the fight against cancer, and we invite you to join us on this journey